Dr Sabine Luik
Chief Medical Officer
Sabine has extensive global industry experience leading teams across regulatory, pharmacovigilance, clinical development, clinical operations, and medical affairs.
As Chief Medical Officer, Sabine is responsible for benefit-risk decision making across the entire asset lifecycle, Safety and Pharmacovigilance, Global Regulatory Affairs, Quality and Risk Management, Medical Writing and building a leading data framework and value chain to maximise our pipeline and marketed products.
Her teams are driven by our purpose across GSK to deliver what matters better and faster, for those who count on us. Prior to joining GSK, Sabine held senior positions in Medical, Regulatory and Pharmacovigilance with Boehringer Ingelheim in the US and Germany including being globally responsible for Regulatory, Safety, Quality, and Epidemiology across the therapeutic areas.
Sabine received her MD from Johannes Gutenberg University (JGU), Mainz, Germany, and her Executive MBA from JGU in cooperation with the McCombs School of Business, University of Texas, Austin. She is a licensed physician in Germany.
Success in medicine development is directly tied to applying diverse views to problem solving. At GSK we constantly work to ensure clinical trial participants are representative of the patient populations affected by the diseases we aim to treat. Trials that reflect the true diversity of the population impacted by a disease – for example a women’s health issue – will lead to better insights in the development of a medicine and how it is prescribed for patients.
Sabine's achievements
2018 – Present
Chief Medical Officer (CMO) for GSK. Since September 2023, the CMO reports directly to our Chief Scientific Officer.
2015 – 2018
Member of the Health Section Governing Board for BIO
2013 – 2018
Membership in senior committees/activity in Efpia/PhRMA
2012 – Present
Member of the International Council on Harmonisation (ICH) Management Committee on behalf of EFPIA
1998 – 2018
Held senior positions in Medical, Regulatory and Pharmacovigilance with Boehringer Ingelheim where she established a global epidemiology team and worked across multiple therapeutic areas.
Education
Received her MD from Johannes Gutenberg University (JGU), Mainz, Germany, and her Executive MBA from JGU in cooperation with the McCombs School of Business, University of Texas, Austin. She is a licensed physician in Germany.
